dGenThera, Nusano Sign Deal for Astatine‑211 Supply

June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a physics company transforming the production of radioisotopes, have announced the signing of a letter of intent to provide dGenThera with access to high‑purity astatine‑211 (At‑211), a best‑in‑class alpha‑emitting isotope for cancer therapy.